SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-21-042519
Filing Date
2021-12-21
Accepted
2021-12-21 07:50:47
Documents
15
Period of Report
2021-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10032081_8k.htm   iXBRL 8-K 37171
2 EXHIBIT 10.1 brhc10032081_ex10-1.htm EX-10.1 32251
3 EXHIBIT 99.1 brhc10032081_ex99-1.htm EX-99.1 16501
7 image00001.jpg GRAPHIC 4147
  Complete submission text file 0001140361-21-042519.txt   245468

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA galt-20211220.xsd EX-101.SCH 3959
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20211220_lab.xml EX-101.LAB 22544
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20211220_pre.xml EX-101.PRE 16066
9 EXTRACTED XBRL INSTANCE DOCUMENT brhc10032081_8k_htm.xml XML 4244
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

IRS No.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 211506846
SIC: 2834 Pharmaceutical Preparations